Q1. What is the difference between dry and wet AMD coding?

Dry (nonexudative) AMD is coded under the H35.31 category, while Wet (exudative) AMD is coded under H35.32. Wet AMD claims typically support therapeutic procedures like intravitreal anti-VEGF injections (CPT 67028), whereas dry AMD focuses on diagnostic monitoring and low-vision management.

Q2. Which modifiers should be used for bilateral intravitreal injections?

Depending on specific payer guidelines, bilateral intravitreal injections are billed either on two separate lines with -RT and -LT modifiers, or on a single line with modifier -50. Always verify your commercial and MAC carrier's billing manual for bilateral injection rules.

Q3. Why are unspecified AMD codes (H35.30) rejected by insurers?

Insurers require specific laterality and disease classification to validate medical necessity, particularly for expensive biologic therapies. Unspecified codes fail pre-payment automated LCD/NCD edits, triggering immediate claim rejections.

Q4. How does Shoreline help ophthalmology practices improve coding accuracy?

Shoreline provides certified coders experienced in ophthalmic surgical procedures, injection billing, and diagnostic imaging. We implement real-time claim scrubbing, conduct regular chart audits, and manage payer appeals to ensure high collection rates.

Medical Coding • Ophthalmology Guidelines

Accurate AMD Coding: Ensuring Proper Documentation & Reimbursement

A comprehensive clinical guide for ophthalmology practices to master Age-Related Macular Degeneration ICD-10 specificity, laterality rules, anti-VEGF injection coding, and medical necessity documentation.

Sharanya Rajmohan Healthcare RCM Specialist

Published Apr 02, 2025

Accurate Age-Related Macular Degeneration AMD Coding

Executive Key Takeaways

Dry vs. Wet AMD Differentiation: Always distinguish nonexudative (H35.31) from exudative (H35.32) disease forms to reflect clinical severity.

Mandatory Laterality Coding: Replace unspecified H35.30 with 6th-character laterality codes (1 for right eye, 2 for left eye, 3 for bilateral) to avoid denials.

Injection CPT & J-Code Linking: Correctly link intravitreal injection CPT 67028 and drug codes (bevacizumab, ranibizumab, aflibercept) to supported diagnoses.

Diagnostic Imaging Justification: Support medical necessity with OCT scan results, visual acuity progression notes, and fundus examination findings.

Table of Contents

1. Understanding AMD Classifications
2. ICD-10 Codes for AMD Coding
3. AMD Documentation Best Practices
4. Common Coding Errors & Solutions
5. Ensuring Proper Reimbursement
6. How Shoreline Supports Ophthalmology RCM
7. Frequently Asked Questions

1. Understanding Age-Related Macular Degeneration (AMD)

Age-related macular degeneration (AMD) is one of the leading causes of irreversible vision impairment and central vision loss among older adults across the United States. Proper AMD coding and clinical documentation are critical for ophthalmology practices to ensure accurate medical billing and receive appropriate payer reimbursement. Without precise age-related macular degeneration documentation, practices face frequent claim denials, payment freezes, and retrospective payer audit risks.

At Shoreline Medical Billing, we specialize in ophthalmology revenue cycle management, helping clinical providers optimize their coding practices, prevent claim rejections, and maximize clean claim reimbursements. In this guide, we explore the essential aspects of AMD coding, best practices for clinical documentation, and proven RCM strategies for ophthalmology clinics.

AMD is a progressive ocular disease affecting the macula, leading to loss of sharp, straight-ahead vision. It is clinically classified into two primary forms:

Clinical Classifications of AMD

1. Dry AMD (Nonexudative or Atrophic): The most common form (representing approximately 85–90% of cases), characterized by the gradual accumulation of drusen and the thinning or breakdown of light-sensitive macula cells.
2. Wet AMD (Exudative or Neovascular): A less common but significantly more severe form, involving abnormal choroidal neovascularization beneath the retina that leaks blood and fluid, leading to rapid central vision deterioration.

Proper clinical classification of AMD is fundamental for accurate billing, as nonexudative and exudative forms require distinct ICD-10 diagnosis codes, procedure links, and ongoing treatment documentation.

2. Primary ICD-10 Codes for AMD Coding

Selecting the highest level of ICD-10 specificity ensures claims are scrubbed and processed without clearinghouse rejection. Key ICD-10 code categories for age-related macular degeneration include:

Comprehensive ICD-10 Code Matrix

H35.30 — Unspecified age-related macular degeneration (Avoid using when laterality or stage is documented)
H35.31 — Nonexudative (Dry) age-related macular degeneration
- H35.311 — Nonexudative age-related macular degeneration, right eye
- H35.312 — Nonexudative age-related macular degeneration, left eye
- H35.313 — Nonexudative age-related macular degeneration, bilateral
H35.32 — Exudative (Wet) age-related macular degeneration
- H35.321 — Exudative age-related macular degeneration, right eye
- H35.322 — Exudative age-related macular degeneration, left eye
- H35.323 — Exudative age-related macular degeneration, bilateral

Accurate selection of these specific diagnosis codes is vital for claim adjudication. Shoreline Medical Billing assists ophthalmology providers in maintaining updated coding rules and eliminating recurring coding errors.

3. Age-Related Macular Degeneration Documentation Best Practices

Comprehensive clinical documentation is essential to demonstrate medical necessity and justify reimbursement for specialized treatments and diagnostic imaging. Medical records should include:

1. Detailed Patient History

Family history of macular degeneration and ocular conditions.
Subjective symptoms such as metamorphopsia, central scotomas, blurred vision, or decreased contrast sensitivity.
Lifestyle and systemic risk factors (smoking history, dietary patterns, cardiovascular disease, UV exposure).

2. Clinical Examination & Diagnostic Findings

Baseline and current Snellen visual acuity test results for each eye.
Dilated slit-lamp fundus biomicroscopy examination findings.
Optical Coherence Tomography (OCT) scan measurements and Fluorescein Angiography (FA) reports.
Documentation of drusen size, geographic atrophy boundaries, or choroidal neovascular membrane (CNVM) activity.

3. Staging and Disease Progression

Classification as early, intermediate, or advanced dry/wet AMD.
Documented changes in retinal thickness or fluid accumulation compared to prior encounters.

4. Treatment Plan & Procedure Documentation

When performing therapeutic procedures such as intravitreal injections (CPT code 67028) or photodynamic therapy, the operative note must explicitly state:

The specific clinical indication and eye treated (right, left, or bilateral).
The exact pharmaceutical agent administered (e.g. bevacizumab / Avastin, ranibizumab / Lucentis, aflibercept / Eylea, faricimab / Vabysmo) with correct HCPCS J-codes and dosage units.
Patient informed consent, sterilization technique, and post-injection monitoring instructions.

4. Common AMD Coding Errors & How to Avoid Them

Errors in AMD coding and documentation frequently trigger costly claim denials. Here are four common mistakes and their direct solutions:

Top 4 Ophthalmology Coding Pitfalls

1. Using Unspecified Codes (H35.30): Assigning H35.30 when laterality is clearly noted in chart notes results in automated clearinghouse rejections. Solution: Always append the exact 6th-character laterality digit (.311, .312, .313).
2. Insufficient Medical Necessity Documentation: Submitting claims for anti-VEGF injections without attached or referenced OCT imaging evidence. Solution: Ensure OCT scan interpretation and reports are integrated into the chart prior to billing.
3. Missing Diagnosis-to-Procedure Link: Failing to link CPT 67028 directly to the specific exudative AMD ICD-10 code. Solution: Configure billing software to enforce strict diagnosis pointer mapping.
4. Omission of Anatomical Modifiers: Billing bilateral or unilateral injection procedures without -RT, -LT, or -50 modifiers. Solution: Verify anatomical modifiers match the clinical narrative on every claim line.

5. Ensuring Proper Reimbursement for AMD Treatments

To maximize cash flow and protect practice margins for high-cost ophthalmic medications and diagnostic imaging, practices should implement these core strategies:

Key Ophthalmology Reimbursement Strategies

Monitor Payer Local Coverage Determinations (LCDs): Payer coverage policies for anti-VEGF medications vary significantly by region and Medicare Administrative Contractor (MAC). Regularly review frequency limits and covered indication lists.
Secure Timely Prior Authorizations: Expensive biologic injectables frequently require prior authorization before administration. Utilize automated prior authorization workflows to eliminate retroactive claim denials.
Conduct Periodic Chart Audits: Perform quarterly internal coding audits to detect documentation gaps, unbilled bilateral services, or modifier mismatches before clearinghouse submission.

6. How Shoreline Simplifies Ophthalmology Revenue Cycle Management

Navigating the complexities of ophthalmic billing, high-cost injectable medications, and modifier compliance requires specialized expertise. Shoreline Medical Billing provides dedicated ophthalmology billing specialists who ensure:

Certified Specialty Coding: Certified coders review all ophthalmic encounters for precise ICD-10, CPT, and HCPCS modifier compliance.
Proactive Denial Management: Instant tracking and rapid appeals for payer rejections, achieving 96% first-pass clean claim rates.
Accelerated Cash Flow: Rapid 24-hour charge scrubbing and electronic remittance posting to keep Days in A/R below benchmark levels.

By partnering with Shoreline Medical Billing, ophthalmology practices achieve audit-ready compliance, minimize administrative burden, and secure maximum allowable reimbursement for every patient encounter.